Status:
COMPLETED
Quality of Erection Study
Lead Sponsor:
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Conditions:
Erectile Dysfunction
Eligibility:
MALE
18-55 years
Phase:
PHASE4
Brief Summary
The study objective is to evaluate the effect that sildenafil citrate has on the hardness of erections in males with erectile dysfunction, based on subject responses to question 5 on the Event Log (ha...
Eligibility Criteria
Inclusion
- Male subjects aged 18-55
- Documented clinical diagnosis of erectile dysfunction confirmed by an IIEF-EF Domain score of less than or equal to 25. (If the subject scores greater than 25 on the IIEF-EF Domain, screening procedures should be terminated.)
Exclusion
- Subjects who have been treated with more than 6 doses of sildenafil citrate or any other phosphodiesterase type 5 (PDE-5) inhibitor such as vardenafil or tadalafil for erectile dysfunction \[Note: subjects should not have taken any PDE-5 inhibitors within 4 weeks prior to the date of screening\]
Key Trial Info
Start Date :
May 1 2005
Trial Type :
INTERVENTIONAL
End Date :
January 1 2006
Estimated Enrollment :
300 Patients enrolled
Trial Details
Trial ID
NCT00159900
Start Date
May 1 2005
End Date
January 1 2006
Last Update
February 1 2021
Active Locations (23)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Investigational Site
Belo Horizonte, Minas Gerais, Brazil, 30130-008
2
Pfizer Investigational Site
Rio de Janeiro, Rio de Janeiro, Brazil, 20551-030
3
Pfizer Investigational Site
Rio Claro, São Paulo, Brazil, 13500-020
4
Pfizer Investigational Site
São Paulo, São Paulo, Brazil, 04044-060